The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index.
The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics
Open accessAbstract
Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS) that initiates a rapid signal transmission in the synapse before its re-uptake into the surrounding glia, specifically astrocytes. The astrocytic glutamate transporters, glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) and their human homologs excitatory amino acid transporter 1 (EAAT1) and 2 (EAAT2), respectively, are the major transporters that take up synaptic glutamate to maintain its optimal extracellular levels, thus preventing its accumulation in the synaptic cleft and the ensuing excitotoxicity. Growing evidence has shown that excitotoxicity is associated with various neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), manganism, ischemia, schizophrenia, epilepsy, and autism. While the mechanisms of neurological disorders are not well understood, the dysregulation of GLAST/GLT-1 may play a significant role in excitotoxicity and associated neuropathogenesis. The expression and function of GLAST/GLT-1 may be dysregulated at the genetic, epigenetic, transcriptional or translational levels, leading to high levels of extracellular glutamate and excitotoxicity. Consequently, understanding the regulatory mechanisms of GLAST/GLT-1 has been an area of interest in developing therapeutics for the treatment of neurological disorders. Pharmacological agents including β-lactam antibiotics, estrogen/selective estrogen receptor modulators (SERMs), growth factors, histone deacetylase inhibitors (HDACi), and translational activators have shown significant efficacy in enhancing the expression and function of GLAST/GLT-1 and glutamate uptake in both in vitro and in vivo settings. This comprehensive review will discuss the regulatory mechanisms of GLAST/GLT-1, their association with neurological disorders, and the pharmacological agents that mediate their expression and function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Epilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., Iwama, H., Nishikawa, T., Ichihara, N., Kikuchi, T., et al. (1997) · Science · doi:10.1126/science.276.5319.1699 · Cited by 1,752
Hay, R. T. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.012 · Cited by 1,622
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 2×
“Moreover, treatment of SOD1 mice with β-lactam antibiotic ceftriaxone attenuated motor symptoms and prolonged survival (Rothstein et al., 2005).”
BackgroundInfluentialSelective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Astrocyte glutamate transport: Review of properties, regulation, and physiological functions
Anderson, C. M., & Swanson, R. A. (2000) · Glia · doi:10.1002/1098-1136(200010)32:1<1::aid-glia10>3.0.co;2-w · Cited by 1,216
Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex
Arriza, J., Fairman, W., Wadiche, J., Murdoch, G., Kavanaugh, M., & Amara, S. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05559.1994 · Cited by 993
Lehre, K. P., & Danbolt, N. C. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-21-08751.1998 · Cited by 678
Lin, C.-L. G., Bristol, L. A., Jin, L., Dykes-Hoberg, M., Crawford, T., Clawson, L., & Rothstein, J. D. (1998) · Neuron · doi:10.1016/s0896-6273(00)80997-6 · Cited by 671
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
dl-threo-β-Benzyloxyaspartate, A Potent Blocker of Excitatory Amino Acid Transporters
Shimamoto, K., Lebrun, B., Yasuda-Kamatani, Y., Sakaitani, M., Shigeri, Y., Yumoto, N., & Nakajima, T. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.195 · Cited by 544
Manganese action in brain function
Takeda, A. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00234-5 · Cited by 538
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Brookmeyer, R., Abdalla, N., Kawas, C. H., & Corrada, M. M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.009 · Cited by 406 · cited 1×
“AD is a chronic neurodegenerative disease characterized by progressive memory loss and cognitive decline (Brookmeyer et al., 2018).”
BackgroundDNA methylation in human diseases
Jin, Z., & Liu, Y. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.01.002 · Cited by 403
Kaufmann, W. E., Cortell, R., Kau, A. S. M., Bukelis, I., Tierney, E., Gray, R. M., Cox, C., Capone, G. T., & Stanard, P. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30229 · Cited by 401
Kim, K., Lee, S., Kegelman, T. P., Su, Z., Das, S. K., Dash, R., Dasgupta, S., Barral, P. M., Hedvat, M., Diaz, P., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22609 · Cited by 395
Role of manganese in neurodegenerative diseases
Bowman, A. B., Kwakye, G. F., Herrero Hernández, E., & Aschner, M. (2011) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2011.08.144 · Cited by 395
Self-citationMolecular pharmacology of glutamate transporters, EAATs and VGLUTs
Shigeri, Y., Seal, R. P., & Shimamoto, K. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.04.004 · Cited by 391
Epigenetic Regulation in Neurodegenerative Diseases
Berson, A., Nativio, R., Berger, S. L., & Bonini, N. M. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.05.005 · Cited by 387
Manganese-Induced Parkinsonism and Parkinson’s Disease: Shared and Distinguishable Features
Kwakye, G., Paoliello, M., Mukhopadhyay, S., Bowman, A., & Aschner, M. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120707519 · Cited by 372
Self-citationMutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures
Jen, J. C., Wan, J., Palos, T. P., Howard, B. D., & Baloh, R. W. (2005) · Neurology · doi:10.1212/01.wnl.0000172638.58172.5a · Cited by 369
Glutamate transporters: animal models to neurologic disease
Maragakis, N. J., & Rothstein, J. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.007 · Cited by 352
Glutamate, Glutamate Receptors, and Downstream Signaling Pathways
Willard, S. S., & Koochekpour, S. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.6426 · Cited by 323
Danger signals in stroke and their role on microglia activation after ischemia
Gülke, E., Gelderblom, M., & Magnus, T. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418774254 · Cited by 321
The role of CREB signaling in Alzheimer’s disease and other cognitive disorders
Saura, C. A., & Valero, J. (2011) · revneuro · doi:10.1515/rns.2011.018 · Cited by 312 · cited 1×
“The transcription factor CREB is known to play an important role in neuronal plasticity and long-term memory formation in the brain (Ortega-Martinez, 2015); and its reduction is consequently implicated in the pathology of AD and other cognitive disorders (Saura and Valero, 2011).”
BackgroundPetr, G. T., Sun, Y., Frederick, N. M., Zhou, Y., Dhamne, S. C., Hameed, M. Q., Miranda, C., Bedoya, E. A., Fischer, K. D., Armsen, W., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4255-14.2015 · Cited by 297 · cited 1×
“Moreover, deletion of GLT-1 (EAAT2) did not modulate EAAT3 expression (Petr et al., 2015).”
BackgroundExtracellular metabolites in the cortex and hippocampus of epileptic patients
Cavus, I., Kasoff, W. S., Cassaday, M. P., Jacob, R., Gueorguieva, R., Sherwin, R. S., Krystal, J. H., Spencer, D. D., & Abi‐Saab, W. M. (2005) · Annals of Neurology · doi:10.1002/ana.20380 · Cited by 292
Phosphorylation and modulation of brain glutamate transporters by protein kinase C.
Casado, M., Bendahan, A., Zafra, F., Danbolt, N. C., Aragón, C., Giménez, C., & Kanner, B. I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74251-3 · Cited by 290
Ortega-Martínez, S. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00046 · Cited by 278
Enzymatic mechanisms regulating protein S-nitrosylation: implications in health and disease
Anand, P., & Stamler, J. S. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0878-z · Cited by 271
A Neuronal Glutamate Transporter Contributes to Neurotransmitter GABA Synthesis and Epilepsy
Sepkuty, J. P., Cohen, A. S., Eccles, C., Rafiq, A., Behar, K., Ganel, R., Coulter, D. A., & Rothstein, J. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06372.2002 · Cited by 264
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., Johnson, J. A., Hayes, D. F., Klein, T., Krauss, R. M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100087 · Cited by 242
Cudkowicz, M. E., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A., Brooks, B., Conwit, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70222-4 · Cited by 241
Excitatory amino acid transporters: keeping up with glutamate
Amara, S. G., & Fontana, A. C. K. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00018-9 · Cited by 240
Positive and negative regulation of EAAT2 by NF‐κB: a role for N‐myc in TNFα‐controlled repression
Sitcheran, R., Gupta, P., Fisher, P. B., & Baldwin, A. S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600555 · Cited by 240
Gegelashvili, G., Danbolt, N. C., & Schousboe, A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69062612.x · Cited by 237
Raghavendra Rao, V. L., Başkaya, M. K., Doğan, A., Rothstein, J. D., & Dempsey, R. J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70052020.x · Cited by 231
Rao, V. L. R., Dogan, A., Todd, K. G., Bowen, K. K., Kim, B.-T., Rothstein, J. D., & Dempsey, R. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01876.2001 · Cited by 227
Zelenaia, O., Schlag, B. D., Gochenauer, G. E., Ganel, R., Song, W., Beesley, J. S., Grinspan, J. B., Rothstein, J. D., & Robinson, M. B. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26465-8 · Cited by 226
Histological effects of givinostat in boys with Duchenne muscular dystrophy
Bettica, P., Petrini, S., D'Oria, V., D'Amico, A., Catteruccia, M., Pane, M., Sivo, S., Magri, F., Brajkovic, S., Messina, S., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.07.002 · Cited by 212
Chen, W., Aoki, C., Mahadomrongkul, V., Gruber, C. E., Wang, G. J., Blitzblau, R., Irwin, N., & Rosenberg, P. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02142.2002 · Cited by 208
Epigenetic mechanisms in neurological and neurodegenerative diseases
Landgrave-Gómez, J., Mercado-Gómez, O., & Guevara-Guzmán, R. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00058 · Cited by 202
Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease
Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., & Dodd, P. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.008 · Cited by 202
Su, Z.-Z., Leszczyniecka, M., Kang, D.-C., Sarkar, D., Chao, W., Volsky, D. J., & Fisher, P. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0136555100 · Cited by 199
Ullensvang, K., Lehre, K. P., Storm‐Mathisen, J., & Danbolt, N. C. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01522.x · Cited by 199
Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation
Chu, K., Lee, S.-T., Sinn, D.-I., Ko, S.-Y., Kim, E.-H., Kim, J.-M., Kim, S.-J., Park, D.-K., Jung, K.-H., Song, E.-C., et al. (2007) · Stroke · doi:10.1161/01.str.0000252091.36912.65 · Cited by 188
Multiple Mechanisms of Transcriptional Repression by YY1
Galvin, K. M., & Shi, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3723 · Cited by 183
Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen
Pawlak, J., Brito, V., Küppers, E., & Beyer, C. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.043 · Cited by 181
Liu, W., Wang, J., Xie, Z.-M., Xu, N., Zhang, G.-F., Jia, M., Zhou, Z., Hashimoto, K., & Yang, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4128-2 · Cited by 169
Glutamate Transporter EAAT2: A New Target For The Treatment Of Neurodegenerative Diseases
Lin, C. G., Kong, Q., Cuny, G. D., & Glicksman, M. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.122 · Cited by 169
Takahashi, K., Kong, Q., Lin, Y., Stouffer, N., Schulte, D. A., Lai, L., Liu, Q., Chang, L., Dominguez, S., Xing, X., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140413 · Cited by 169
David, C. N., Frias, E. S., Szu, J. I., Vieira, P. A., Hubbard, J. A., Lovelace, J., Michael, M., Worth, D., McGovern, K. E., Ethell, I. M., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005643 · Cited by 164
The potential role of neuroinflammation and transcription factors in Parkinson disease
Tiwari, P. C., & Pal, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rpal · Cited by 164
Yang, L.-C., Zhang, Q.-G., Zhou, C.-F., Yang, F., Zhang, Y.-D., Wang, R.-M., & Brann, D. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009851 · Cited by 163 · cited 1×
“One such mechanism is the release of brain-derived neurotrophic factor (BDNF), which promoted neuronal survival and cognitive function in an ischemic rat model (Yang et al., 2010).”
BackgroundGLT-1 Loss Accelerates Cognitive Deficit Onset in an Alzheimer's Disease Animal Model
Mookherjee, P., Green, P. S., Watson, G. S., Marques, M. A., Tanaka, K., Meeker, K. D., Meabon, J. S., Li, N., Zhu, P., Olson, V. G., et al. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110503 · Cited by 163
Caspase-3 Cleaves and Inactivates the Glutamate Transporter EAAT2
Boston-Howes, W., Gibb, S. L., Williams, E. O., Pasinelli, P., Brown, R. H., & Trotti, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600653200 · Cited by 161
Regulation of Histone Acetylation by Autophagy in Parkinson Disease
Park, G., Tan, J., Garcia, G., Kang, Y., Salvesen, G., & Zhang, Z. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675488 · Cited by 160
Aida, T., Yoshida, J., Nomura, M., Tanimura, A., Iino, Y., Soma, M., Bai, N., Ito, Y., Cui, W., Aizawa, H., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.26 · Cited by 158
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection
Kong, Q., Chang, L.-C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., Ibabao, B., Lin, Y., Stouffer, N., Mukhopadhyay, C. D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66163 · Cited by 156
Inhibition of the High‐Affinity Brain Glutamate Transporter GLAST‐1 via Direct Phosphorylation
Conradt, M., & Stoffel, W. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68031244.x · Cited by 156
Zschocke, J., Bayatti, N., Clement, A. M., Witan, H., Figiel, M., Engele, J., & Behl, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502581200 · Cited by 154
Parkin, G. M., Udawela, M., Gibbons, A., & Dean, B. (2018) · World Journal of Psychiatry · doi:10.5498/wjp.v8.i2.51 · Cited by 154
Kalandadze, A. G., Wu, Y., & Robinson, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203771200 · Cited by 152
Structural Features of the Glutamate Transporter Family
Slotboom, D. J., Konings, W. N., & Lolkema, J. S. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.2.293-307.1999 · Cited by 151
GLT-1: The elusive presynaptic glutamate transporter
Rimmele, T. S., & Rosenberg, P. A. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.010 · Cited by 151
Estrogen and tamoxifen reverse manganese‐induced glutamate transporter impairment in astrocytes
Lee, E.-S., Sidoryk‐Wȩgrzynowicz, M., Jiang, H., Yin, Z., & Aschner, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06105.x · Cited by 150
Self-citationThe Yin and Yang of YY1 in the nervous system
He, Y., & Casaccia‐Bonnefil, P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05486.x · Cited by 149
Close, J., Gümüşçü, B., & Reh, T. A. (2005) · Development · doi:10.1242/dev.01882 · Cited by 149
Bennett, S. A., Tanaz, R., Cobos, S. N., & Torrente, M. P. (2018) · Translational research · doi:10.1016/j.trsl.2018.10.002 · Cited by 143
Bridges, R. J., & Esslinger, C. S. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.002 · Cited by 142
Pathophysiology of manganese-associated neurotoxicity
Racette, B. A., Aschner, M., Guilarte, T. R., Dydak, U., Criswell, S. R., & Zheng, W. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.010 · Cited by 141
Self-citationLiang, Z., Valla, J., Sefidvash-Hockley, S., Rogers, J., & Li, R. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00779.x · Cited by 141
Li, L., Toan, S. V., Zelenaia, O. A., Watson, D. J., Wolfe, J. H. N., Rothstein, J. D., & Robinson, M. B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03743.x · Cited by 140
Romera, C., Hurtado, O., Mallolas, J., Pereira, M. P., Morales, J. R., Romera, A., Serena, J. L., Vivancos, J., Nombela, F., Lorenzo, P. L., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600438 · Cited by 140
Regulation of glial glutamate transporter expression by growth factors
Figiel, M., Maucher, T., Rozyczka, J., Bayatti, N., & Engele, J. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00134-1 · Cited by 139
Neuronal activity regulates glutamate transporter dynamics in developing astrocytes
Benediktsson, A. M., Marrs, G. S., Tu, J. C., Worley, P. F., Rothstein, J. D., Bergles, D. E., & Dailey, M. E. (2011) · Glia · doi:10.1002/glia.21249 · Cited by 139
Decker, J. M., Krüger, L., Sydow, A., Dennissen, F. J. A., Šišková, Z., Mandelkow�, E., & Mandelkow, E. (2016) · EMBO Reports · doi:10.15252/embr.201541439 · Cited by 139
Regulation of brain glutamate metabolism by nitric oxide and S-nitrosylation
Raju, K., Doulias, P., Evans, P., Krizman, E. N., Jackson, J. G., Horyn, O., Daikhin, Y., Nissim, I. B., Yudkoff, M., Nissim, I., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa4312 · Cited by 135
Bauer, D., Haroutunian, V. H., Meador‐Woodruff, J. H., & McCullumsmith, R. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.07.025 · Cited by 133
Yoo, Y.-E., & Ko, C. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.003 · Cited by 132
Estrogen and SERM neuroprotection in animal models of Parkinson's disease
Morissette, M., Al-Sweidi, S., Callier, S., & Paolo, T. D. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.008 · Cited by 132
Early life experience drives structural variation of neural genomes in mice
Bedrosian, T. A., Quayle, C., Novaresi, N., & Gage, F. H. (2018) · Science · doi:10.1126/science.aah3378 · Cited by 131 · cited 1×
“YY1 is implicated in neurodegenerative disorders including PD, ALS, AD, Charcot-Marie-Tooth disease and Rett syndrome (Aubry et al., 2015; Bedrosian et al., 2018; Forlani et al., 2010; Nowak et al., 2006; Ratajewski and Pulaski, 2009; Tiwari and Pal, 2017; Yin et al., 2018).”
BackgroundTuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases
Selvi, B. R., Cassel, J., Kundu, T. K., & Boutillier, A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.08.012 · Cited by 130
Meyer, T., Fromm, A., Münch, C., Schwalenstöcker, B., Fray, A. E., Ince, P. G., Stamm, S., Grön, G., Ludolph, A. C., & Shaw, P. J. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00196-3 · Cited by 128
Riluzole elevates GLT-1 activity and levels in striatal astrocytes
Carbone, M., Duty, S., & Rattray, M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.017 · Cited by 127
Boehmer, C., Henke, G., Schniepp, R., Palmada, M., Rothstein, J. D., Bröer, S., & Lang, F. J. W. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01937.x · Cited by 120
Bauer, D., Gupta, D. S., Harotunian, V., Meador‐Woodruff, J. H., & McCullumsmith, R. E. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.012 · Cited by 118
Age and Alzheimer’s disease gene expression profiles reversed by the glutamate modulator riluzole
Pereira, A. C., Gray, J. D., Kogan, J. F., Davidson, R. L., Rubin, T. G., Okamoto, M., Morrison, J. H., & McEwen, B. S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.33 · Cited by 116
Huang, K., Kang, M. H., Askew, C. E., Kang, R., Sanders, S. S., Wan, J., Davis, N. G., & Hayden, M. R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.027 · Cited by 116
Harvey, B. K., Airavaara, M., Hinzman, J. M., Wires, E. M., Chiocco, M. J., Howard, D. B., Shen, H., Gerhardt, G. A., Hoffer, B. J., & Wang, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022135 · Cited by 115
Silvestrin, R. B., Bambini-Júnior, V., Galland, F., Bobermin, L. D., Quincozes‐Santos, A., Abib, R. T., Zanotto, C., Batassini, C., Brolese, G., Gonçalves, C., et al. (2012) · Brain Research · doi:10.1016/j.brainres.2012.11.048 · Cited by 113
EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders
Lauriat, T. L., & McInnes, L. A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002065 · Cited by 112
Chung, E. K. Y., Chen, L. W., Chan, Y., & Yung, K. K. L. (2008) · The Journal of Comparative Neurology · doi:10.1002/cne.21852 · Cited by 112
Neurotransmitters in the mediation of cerebral ischemic injury
Mayor, D., & Tymianski, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.050 · Cited by 112
Boehmer, C., Palmada, M., Rajamanickam, J., Schniepp, R., Amara, S., & Lang, F. J. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03629.x · Cited by 110
Mallolas, J., Hurtado, O., Castellanos, M., Blanco, M., Sobrino, T., Serena, J. L., Vivancos, J., Castillo, J., Lizasoaín, I., Moro, M. Á., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051979 · Cited by 110
Oncogene AEG-1 Promotes Glioma-Induced Neurodegeneration by Increasing Glutamate Excitotoxicity
Lee, S., Kim, K., Kegelman, T. P., Dash, R., Das, S. K., Choi, J. K., Emdad, L., Howlett, E. L., Jeon, H. Y., Su, Z. Z., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0782 · Cited by 110
Löschmann, P. A., de Groote, C., Smith, L. A., Wüllner, U., Fischer, G., Kemp, J. A., Jenner, P. G., & Klockgether, T. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.018 · Cited by 109
Aubry, S., Shin, W., Crary, J. F., Lefort, R., Qureshi, Y. H., Lefebvre, C., Califano, A., & Shelanski, M. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120352 · Cited by 106 · cited 1×
“YY1 is implicated in neurodegenerative disorders including PD, ALS, AD, Charcot-Marie-Tooth disease and Rett syndrome (Aubry et al., 2015; Bedrosian et al., 2018; Forlani et al., 2010; Nowak et al., 2006; Ratajewski and Pulaski, 2009; Tiwari and Pal, 2017; Yin et al., 2018).”
BackgroundKarki, P., Webb, A., Smith, K., Johnson, J., Lee, K., Son, D., Aschner, M., & Lee, E.-S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01176-13 · Cited by 106
Self-citationHigashimori, H., Schin, C. S., Chiang, M. S. R., Morel, L., Shoneye, T. A., Nelson, D. L., & Yang, Y. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1069-16.2016 · Cited by 105
Ma, Y. J., Hill, D. F., Junier, M., Costa, M. E., Felder, S., & Ojeda, S. R. (1994) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1994.1029 · Cited by 105
Stipursky, J., & Gomes, F. C. A. (2007) · Glia · doi:10.1002/glia.20522 · Cited by 101
García‐Tardón, N., González‐González, I. M., de Villarreal, J. M., Fernández-Sánchez, E., Giménez, C., & Zafra, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355909 · Cited by 101
Kong, Q., Takahashi, K., Schulte, D. A., Stouffer, N., Lin, Y., & Lin, C. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.032 · Cited by 100
Taming Glutamate Excitotoxicity: Strategic Pathway Modulation for Neuroprotection
Jia, M., Njapo, S. A. N., Rastogi, V., & Hedna, V. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0225-3 · Cited by 98
The importance of the excitatory amino acid transporter 3 (EAAT3)
Bjørn-Yoshimoto, W. E., & Underhill, S. M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.05.007 · Cited by 98
Karki, P., Webb, A., Smith, K., Lee, K., Son, D.-S., Aschner, M., & Lee, E.-S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.483826 · Cited by 97
Self-citationHarmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression
Li, Y., Sattler, R., Yang, E. J., Nunes, A., Ayukawa, Y., Akhtar, S., Ji, G., Zhang, P.-W., & Rothstein, J. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.016 · Cited by 97
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson’s disease model
Zhang, Y., He, X., Meng, X., Wu, X., Tong, H., Zhang, X., & Qu, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.454 · Cited by 97
The transcription factor Yin Yang 1 is an activator of BACE1 expression
Nowak, K., Lange‐Dohna, C., Zeitschel, U., Günther, A., Lüscher, B., Robitzki, A. A., Perez‐Polo, R. J., & Roßner, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03692.x · Cited by 95
García‐Bueno, B., Caso, J. R., Perez‐Nievas, B. G., Lorenzo, P. L., & Leza, J. C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301252 · Cited by 94
GPR30 Regulates Glutamate Transporter GLT-1 Expression in Rat Primary Astrocytes
Lee, E.-S., Sidoryk‐Wȩgrzynowicz, M., Wang, N., Webb, A., Son, D.-S., Lee, K., & Aschner, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.341867 · Cited by 94
Self-citationGuan, T., Qian, Y., Tang, X., Huang, M., Huang, L., Li, Y., & Sun, H. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22671 · Cited by 92
Koeberle, P. D., & Bähr, M. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402281 · Cited by 91
Association Studies of Neurotransmitter Gene Polymorphisms in Alcoholic Caucasians
Foley, P. F., Loh, E., INNES, D. J., Williams, S. M., Tannenberg, A. E. G., Harper, C., & Dodd, P. R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.005 · Cited by 88
Karki, P., Webb, A., Zerguine, A. M., Choi, J., Son, D., & Lee, E.-S. (2014) · Glia · doi:10.1002/glia.22679 · Cited by 87
Self-citationRodriguez-Kern, A., Gegelashvili, M., Schousboe, A., Zhang, J., Sung, L., & Gegelashvili, G. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00023-8 · Cited by 80
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649349 · Cited by 80
Lee, E.-S., Sidoryk‐Wȩgrzynowicz, M., Yin, Z., Webb, A., Son, D., & Aschner, M. (2012) · Glia · doi:10.1002/glia.22329 · Cited by 78
Self-citationHistone methylation patterns in astrocytes are influenced by age following ischemia
Chisholm, N. C., Henderson, M. L., Selvamani, A., Park, M. J., Dindot, S. V., Miranda, R. C., & Sohrabji, F. (2015) · Epigenetics · doi:10.1080/15592294.2014.1001219 · Cited by 75
Rao, S., Saternos, H. C., Goodwani, S., & Sari, Y. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3868-3 · Cited by 74
CNS region‐specific regulation of glial glutamate transporter expression
Schlüter, K., Figiel, M., Rozyczka, J., & Engele, J. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02130.x · Cited by 74
Karki, P., Kim, C., Smith, K., Son, D., Aschner, M., & Lee, E.-S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.649327 · Cited by 74
Self-citationKoeglsperger, T., Li, S., Brenneis, C., Saulnier, J. L., Mayo, L., Carrier, Y., Selkoe, D. J., & Weiner, H. L. (2013) · Glia · doi:10.1002/glia.22490 · Cited by 73 · cited 2×
“…↑EAAT2/GLT-1 TGF-α, PI3K-Akt In vitro; manganism (Figiel et al., 2003; Lee et al., 2012b) TGF-β1 ↑EAAT1/GLAST, ↑EAAT2/GLT-1 TGF-β1 In vitro and in vivo (Close et al., 2005; Koeglsperger et al., 2013; Stipursky and Gomes, 2007) BDNF ↑EAAT1/GLAST, ↑EAAT2/GLT-1 BDNF-TrkB, CREB, NF-κB In…”
BackgroundKarki, P., Smith, K., Johnson, J., & Lee, E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.010 · Cited by 73
Self-citationMotor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2
Foran, E., Bogush, A. I., Goffredo, M., Roncaglia, P., Gustincich, S., Pasinelli, P., & Trotti, D. (2011) · Glia · doi:10.1002/glia.21218 · Cited by 73
Chen, N., Huang, S., Chen, W.-F., Chen, C., Lu, C.-H., Chen, C., Yang, S., Wang, H., & Wen, Z. (2013) · Journal of Pain · doi:10.1016/j.jpain.2013.08.010 · Cited by 73
N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease
Ferrer, I., & Blanco, R. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00062-0 · Cited by 72
Manganese Neurotoxicity: a Focus on Glutamate Transporters
Karki, P., Lee, E.-S., & Aschner, M. (2013) · Annals of Occupational and Environmental Medicine · doi:10.1186/2052-4374-25-4 · Cited by 71
Self-citationTortarolo, M., Crossthwaite, A. J., Conforti, L., Spencer, J. P. E., Williams, R. J., Bendotti, C., & Rattray, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02208.x · Cited by 69
Kügler, P., & Schleyer, V. (2004) · Hippocampus · doi:10.1002/hipo.20015 · Cited by 69
Sheldon, A. L., González, M. I., Krizman, E. N., Susarla, B. T. S., & Robinson, M. B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.07.010 · Cited by 69
Forlani, G., Giarda, E., Ala, U., Cunto, F. D., Salani, M., Tupler, R. G., Kilstrup‐Nielsen, C., & Landsberger, N. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq214 · Cited by 69
Kim, S., Choi, S., Chao, W., & Volsky, D. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02128.x · Cited by 67
González‐González, I. M., García‐Tardón, N., Giménez, C., & Zafra, F. (2008) · Glia · doi:10.1002/glia.20670 · Cited by 67
Weller, M. L., Stone, I. M., Goss, A., Rau, T., Rova, C. R. L., & Poulsen, D. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.059 · Cited by 66
DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells
Zschocke, J., Allritz, C., Engele, J., & Rein, T. (2007) · Glia · doi:10.1002/glia.20497 · Cited by 66
The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex
Chi, B., O’Connell, J. D., Iocolano, A. D., Coady, J. A., Yu, Y., Gangopadhyay, J. P., Gygi, S. P., & Reed, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1093 · Cited by 66
Feng, D., Wang, W., Dong, Y., Wu, L., Huang, J., Ma, Y., Zhang, Z., Wu, S., Gao, G., & Qin, H. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.053 · Cited by 65
Carbone, M., Duty, S., & Rattray, M. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-38 · Cited by 64
Sari, Y., Toalston, J. E., Rao, S., & Bell, R. L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.04.004 · Cited by 64
Vallejo‐Illarramendi, A., Domercq, M., & Matute, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03370.x · Cited by 63
Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia
Spangaro, M., Bosia, M., Zanoletti, A., Bechi, M., Cocchi, F., Pirovano, A., Lorenzi, C., Bramanti, P., Benedetti, F., Smeraldi, E., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.06.030 · Cited by 63
Ji, Y.-F., Zhou, L., Xie, Y., Xu, S., Zhu, J., Teng, P., Shao, C., Wang, Y., Luo, J., & Shen, Y. (2013) · Glia · doi:10.1002/glia.22566 · Cited by 62
O'Donovan, S. M., Hasselfeld, K., Bauer, D., Simmons, M. S., Roussos, P., Haroutunian, V. H., Meador‐Woodruff, J. H., & McCullumsmith, R. E. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.74 · Cited by 62
Foran, E., Rosenblum, L. T., Bogush, A. I., Pasinelli, P., & Trotti, D. (2014) · Glia · doi:10.1002/glia.22677 · Cited by 61
Dunlop, J., McIlvain, H. B., Carrick, T. A., Jow, B., Lü, Q., Kowal, D. M., Lin, S., Greenfield, A., Grosanu, C., Fan, K. Y., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012005 · Cited by 60
Yamashita, A., Makita, K., Kuroiwa, T., & Tanaka, K. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.03.007 · Cited by 59
Pampliega, O., Domercq, M., Villoslada, P., Sepulcre, J., Antigüedad, A. R., & Matute, C. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.01.011 · Cited by 59
Rao, S., Goodwani, S., Bell, R. L., Wei, Y., Boddu, S. H. S., & Sari, Y. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.038 · Cited by 59
β-Catenin signaling positively regulates glutamate uptake and metabolism in astrocytes
Lutgen, V., Narasipura, S. D., Sharma, A. S., Min, S., & Al‐Harthi, L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0691-7 · Cited by 59
Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies
Garcia‐Esparcia, P., Lucena, D. D., Ainciburu, M., Torrejón-Escribano, B., Carmona, M., Llorens, F., & Ferrer, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00122 · Cited by 59
Wilson, J. M. B., Khabazian, I., Pow, D. V., Craig, U. K., & Shaw, C. A. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:105 · Cited by 58
Šerý, O., Sultana, N., Kashem, M. A., Pow, D. V., & Balcar, V. J. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1605-2 · Cited by 57
Evidence that protein kinase Cα interacts with and regulates the glial glutamate transporter GLT‐1
González, M. I., Susarla, B. T. S., & Robinson, M. B. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03330.x · Cited by 57
Kawahara, K., Hosoya, R., Sato, H., Tanaka, M., Nakajima, T., & Iwabuchi, S. (2002) · Glia · doi:10.1002/glia.10133 · Cited by 57
Kim, R., Sepulveda-Orengo, M. T., Healey, K. L., Williams, E. A., & Reissner, K. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.019 · Cited by 57
Sułkowski, G., Dąbrowska‐Bouta, B., Salińska, E., & Strużyńska, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113954 · Cited by 56
Karki, P., Smith, K., Johnson, J., Aschner, M., & Lee, E.-S. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.08.002 · Cited by 56
Self-citationCysteine Transport through Excitatory Amino Acid Transporter 3 (EAAT3)
Watts, S. D., Torres-Salazar, D., Divito, C. B., & Amara, S. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109245 · Cited by 55 · cited 1×
“, 1996), but has been shown to serve as a cysteine transporter (Watts et al., 2014).”
BackgroundModulation of Human Glutamate Transporter Activity by Phorbol Ester
Ganel, R., & Crosson, C. E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70030993.x · Cited by 55
Glutamate‐dependent transcriptional regulation of GLAST/EAAT1: a role for YY1
Rosas‐Madrigal, S., Vargas, M. A., López‐Bayghen, E., & Ortega, A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04517.x · Cited by 54
17β-estradiol and tamoxifen protect mice from manganese-induced dopaminergic neurotoxicity
Pajarillo, E. A. B., Johnson, J., Kim, J., Karki, P., Son, D., Aschner, M., & Lee, E.-S. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.11.008 · Cited by 53
Self-citationPetr, G. T., Schultheis, L. A., Hussey, K. C., Sun, Y., Dubinsky, J. M., Aoki, C. J., & Rosenberg, P. A. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12202 · Cited by 51
Cimarosti, H., Jones, N. M., O’Shea, R. D., Pow, D. V., Salbego, C. G., & Beart, P. M. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.006 · Cited by 51
The prodromes of Parkinson's disease
Rees, R. N., Noyce, A. J., & Schrag, A. E. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14269 · Cited by 51
Peacey, E., Miller, C. C. J., Dunlop, J., & Rattray, M. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052829 · Cited by 50
Bonde, C., Sarup, A., Schousboe, A., Gegelashvili, G., Noraberg, J., & Zimmer, J. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00025-1 · Cited by 49
Karki, P., Hong, P., Johnson, J., Pajarillo, E. A. B., Son, D., Aschner, M., & Lee, E.-S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0709-x · Cited by 49
Self-citationJohnson, J., Pajarillo, E. A. B., Karki, P., Kim, J., Son, D., Aschner, M., & Lee, E.-S. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.05.001 · Cited by 49
Self-citationHagiwara, T., Tanaka, K., Takai, S., Maeno-Hikichi, Y., Mukainaka, Y., & Wada, K. (1996) · Genomics · doi:10.1006/geno.1996.0226 · Cited by 47
BDNF regulates GLAST and glutamine synthetase in mouse retinal Müller cells
Dai, M., Xia, X., & XIONG, S. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22762 · Cited by 47
Kalandadze, A. G., Wu, Y., Fournier, K. M., & Robinson, M. B. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0839-04.2004 · Cited by 47
Perkins, E., Clarkson, Y. L., Šuminaite, D., Lyndon, A. R., Tanaka, K., Rothstein, J. D., Skehel, P., Wyllie, D. J. A., & Jackson, M. T. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy169 · Cited by 47
Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy
Young, D., Fong, D. M., Lawlor, P. A., Wu, A. J., Mouravlev, A., McRae, M., Glass, M., Dragunow, M., & During, M. J. (2014) · Gene Therapy · doi:10.1038/gt.2014.82 · Cited by 45
Differential SLC1A2 Promoter Methylation in Bipolar Disorder With or Without Addiction
Jia, Y., Choi, Y., Ayers-Ringler, J. R., Biernacka, J. M., Geske, J. R., Lindberg, D. R., McElroy, S. L., Frye, M. A., Choi, D., & Veldić, M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00217 · Cited by 45
Poletti, S., Riberto, M., Vai, B., Ghiglino, D., Lorenzi, C., Vitali, A., Brioschi, S., Locatelli, C., Serretti, A., Colombo, C., et al. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1138-7 · Cited by 45
Johnson, J., Pajarillo, E. A. B., Taka, E., Reams, R. R., Son, D., Aschner, M., & Lee, E.-S. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.06.007 · Cited by 44
Self-citationJagadapillai, R., Mellen, N. M., Sachleben, L. R., & Gozal, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100230 · Cited by 42
Genetic variation of the glutamate transporter EAAT2 gene and vulnerability to alcohol dependence
Sander, T., Ostapowicz, A., Samochowiec, J., Smolka, M. N., Winterer, G., & Schmidt, L. (2000) · Psychiatric Genetics · doi:10.1097/00041444-200010030-00001 · Cited by 42
Myles‐Worsley, M., Tiobech, J., Browning, S. R., Korn, J., Goodman, S. J., Gentile, K. L., Melhem, N., Byerley, W., Faraone, S. V., & Middleton, F. A. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32125 · Cited by 42
Rosenblum, L. T., Markandaiah, S. S., Ghosh, B., Foran, E., Lepore, A. C., Pasinelli, P., & Trotti, D. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.03.014 · Cited by 42
Dunlop, J., Eliasof, S. D., Stack, G., McIlvain, H. B., Greenfield, A., Kowal, D. M., Petroski, R. E., & Carrick, T. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705509 · Cited by 41
Valproate-dependent transcriptional regulation of GLAST/EAAT1 expression: Involvement of Ying-Yang 1
Aguirre, G., Rosas‐Madrigal, S., López‐Bayghen, E., & Ortega, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.01.015 · Cited by 41
Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease
Ferrarese, C., Tremolizzo, L., Rigoldi, M., Sala, G., Brighina, L., Ricci, G., Albizzati, M. G., Piolti, R., Crosti, F., Dalpr�, L., et al. (2001) · Neurological Sciences · doi:10.1007/s100720170049 · Cited by 39
Sander, T., Berlin, W., Ostapowicz, A., Samochowiec, J., Gscheidel, N., & Hoehe, M. R. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(00)00120-0 · Cited by 39
Yamada, T., Kawahara, K., Kosugi, T., & Tanaka, M. (2006) · Neurochemical Research · doi:10.1007/s11064-005-9077-4 · Cited by 38
Delyfer, M., Simonutti, M., Neveux, N., Léveillard, T., & Sahel, J. (2005) · PubMed · Cited by 37
Ryan, R. M., Kortt, N. C., Sirivanta, T., & Vandenberg, R. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06796.x · Cited by 37
Shen, J., Rothman, D. L., Behar, K. L., & Xu, S. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.102 · Cited by 37
Qian, Y., Guan, T., Tang, X., Huang, L., Huang, M., Li, Y., Sun, H., Yu, R. M., & Zhang, F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.095 · Cited by 37
Han, X., Yang, L., Du, H., Sun, Q., Wang, X., Cong, L., Liu, X., Yin, L., Li, S., & Du, Y. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0268-5 · Cited by 37
Ibáñez, I., Díez-Guerra, F. J., Giménez, C., & Zafra, F. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.042 · Cited by 37
Properties of excitatory amino acid transport in the human U373 astrocytoma cell line
Dunlop, J., Lou, Z., & McIlvain, H. B. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01714-x · Cited by 36
Muñoz‐Ballester, C., Berthier, A., Viana, R., & Sanz, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.03.008 · Cited by 36
Colón, J. M., Torrado, A. I., Cajigas, Á., Santiago, J. M., Salgado, I. K., Arroyo, Y., & Miranda, J. D. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4111 · Cited by 35 · cited 1×
“Some SERMs, such as tamoxifen and raloxifene, can act as ER agonists in the brain and increase expression of GLAST/GLT-1 at the transcriptional level (Colon et al., 2016; Morissette et al., 2008; Pajarillo et al., 2018; Pandey et al., 2016).”
BackgroundKim, S., Chao, W., Choi, S., & Volsky, D. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01958.x · Cited by 35
Cited by
Teleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders
Brandebura, A. N., Paumier, A., Onur, T. S., & Allen, N. J. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00641-1 · Cited by 427
Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells
Belov Kirdajova, D., Kriska, J., Tureckova, J., & Anderova, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00051 · Cited by 428
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M. E., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 374
Metadata
- Authors
- Pajarillo, E., Rizor, A., Lee, J., Aschner, M., & Lee, E.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 161
- Pages
- 107559
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2921594363
- Cited by
- 478
- References
- 235
- FWCI
- 15.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.